Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM.

Oncologist. 2019 Oct 11. pii: theoncologist.2018-0528. doi: 10.1634/theoncologist.2018-0528. [Epub ahead of print]

PMID:
31604903
2.

Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.

Li G, Pavlick D, Chung JH, Bauer T, Tan BA, Peguero J, Ward P, Kallab A, Bufill J, Hoffman A, Sadiq A, Edenfield J, He J, Cooke M, Hughes J, Forcier B, Nahas M, Stephens P, Ali SM, Schrock AB, Ross JS, Miller VA, Gregg JP.

J Gastrointest Oncol. 2019 Oct;10(5):831-840. doi: 10.21037/jgo.2019.05.05.

3.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV.

Cancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3.

PMID:
31588020
4.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG.

J Clin Invest. 2019 Oct 1;129(10):4276-4289. doi: 10.1172/JCI128227.

5.

Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].

Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM.

Lung Cancer. 2019 Aug 22. pii: S0169-5002(19)30614-2. doi: 10.1016/j.lungcan.2019.08.013. [Epub ahead of print] No abstract available.

6.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Aug 22. pii: S1525-1578(19)30358-7. doi: 10.1016/j.jmoldx.2019.06.011. [Epub ahead of print]

7.

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.

Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS.

Clin Cancer Res. 2019 Oct 1;25(19):5961-5971. doi: 10.1158/1078-0432.CCR-18-4159. Epub 2019 Aug 9.

PMID:
31399473
8.

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Chu LP, Franck D, Parachoniak CA, Gregg JP, Moore MG, Farwell DG, Rao S, Heilmann AM, Erlich RL, Ross JS, Miller VA, Ali S, Riess JW.

Oncologist. 2019 Oct;24(10):1305-1308. doi: 10.1634/theoncologist.2019-0230. Epub 2019 Aug 7.

PMID:
31391294
9.

Tailored medication adherence incentives for high-risk children with asthma: a pilot study.

Kenyon CC, Sundar KG, Gruschow SM, Quarshie WO, Feudtner C, Bryant-Stephens TC, Miller VA.

J Asthma. 2019 Aug 7:1-7. doi: 10.1080/02770903.2019.1648503. [Epub ahead of print]

PMID:
31389724
10.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0214. doi: 10.1634/theoncologist.2019-0214. [Epub ahead of print]

PMID:
31292271
11.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J.

Oncologist. 2019 Jun 27. pii: theoncologist.2019-0121. doi: 10.1634/theoncologist.2019-0121. [Epub ahead of print]

PMID:
31249137
12.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

13.

Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio JA, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich AC, Ali SM, Chung JH, Reddy P, Miller VA, Schrock AB, Gay LM, Ross JS, Jacob JM.

Eur Urol Focus. 2019 Sep;5(5):748-755. doi: 10.1016/j.euf.2019.05.012. Epub 2019 May 27.

PMID:
31147264
14.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Oct;24(10):1340-1347. doi: 10.1634/theoncologist.2019-0034. Epub 2019 Apr 30.

PMID:
31040255
15.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.

Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.

PMID:
31038663
16.

Changes Over Time in Good-Parent Beliefs Among Parents of Children With Serious Illness: A Two-Year Cohort Study.

Hill DL, Faerber JA, Li Y, Miller VA, Carroll KW, Morrison W, Hinds PS, Feudtner C.

J Pain Symptom Manage. 2019 Aug;58(2):190-197. doi: 10.1016/j.jpainsymman.2019.04.018. Epub 2019 Apr 23.

PMID:
31026508
17.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

PMID:
31011206
18.

Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.

Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R.

Cancer Immunol Res. 2019 Jun;7(6):866-873. doi: 10.1158/2326-6066.CIR-18-0716. Epub 2019 Apr 19.

PMID:
31003990
19.

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O'Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA.

JAMA. 2019 Apr 9;321(14):1391-1399. doi: 10.1001/jama.2019.3241.

20.

Interprofessional Teamwork During Family Meetings in the Pediatric Cardiac Intensive Care Unit.

Walter JK, Sachs E, Schall TE, Dewitt AG, Miller VA, Arnold RM, Feudtner C.

J Pain Symptom Manage. 2019 Jun;57(6):1089-1098. doi: 10.1016/j.jpainsymman.2019.03.002. Epub 2019 Mar 12.

PMID:
30876957
21.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N.

Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.

22.

Dynamic formation of stable current-driven plasma jets.

Underwood TC, Loebner KTK, Miller VA, Cappelli MA.

Sci Rep. 2019 Feb 22;9(1):2588. doi: 10.1038/s41598-019-39827-6.

23.

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.

Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM.

Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22.

PMID:
30796031
24.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
25.

Correction: PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors.

Croessmann S, Sheehan JH, Lee KM, Sliwoski G, He J, Nagy R, Riddle D, Mayer IA, Balko JM, Lanman R, Miller VA, Cantley LC, Meiler J, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1432. doi: 10.1158/1078-0432.CCR-18-4269. No abstract available.

PMID:
30770491
26.

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

Boussemart L, Nelson A, Wong M, Ross JS, Sosman J, Mehnert J, Daniels G, Kendra K, Ali SM, Miller VA, Schrock AB.

Oncologist. 2019 May;24(5):657-663. doi: 10.1634/theoncologist.2018-0271. Epub 2019 Jan 25.

27.

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

Tsou TC, Gowen K, Ali SM, Miller VA, Schrock AB, Lovly CM, Reckamp KL.

J Thorac Oncol. 2019 Feb;14(2):e29-e30. doi: 10.1016/j.jtho.2018.10.169. No abstract available.

PMID:
30683295
28.

The Role of Cognitive and Psychosocial Maturity in Type 1 Diabetes Management.

Silva K, Miller VA.

J Adolesc Health. 2019 May;64(5):622-630. doi: 10.1016/j.jadohealth.2018.10.294. Epub 2019 Jan 14.

PMID:
30655120
29.

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.

Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R.

Cancer. 2019 Apr 1;125(7):1185-1199. doi: 10.1002/cncr.31921. Epub 2018 Dec 24.

30.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, Chalmers Z, Lotem M, Gibney G, Russell J, Chmielowski B, Ross JS, Stephens PJ, Miller VA, Ali SM.

J Am Acad Dermatol. 2019 Jun;80(6):1780-1782. doi: 10.1016/j.jaad.2018.12.020. Epub 2018 Dec 18. No abstract available.

31.

Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.

Neilsen BK, Sleightholm R, McComb R, Ramkissoon SH, Ross JS, Corona RJ, Miller VA, Cooke M, Aizenberg MR.

J Neurooncol. 2019 Mar;142(1):111-118. doi: 10.1007/s11060-018-03070-2. Epub 2018 Dec 9.

PMID:
30535594
32.

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.

Sigal DS, Bhangoo MS, Hermel JA, Pavlick DC, Frampton G, Miller VA, Ross JS, Ali SM.

Oncotarget. 2018 Nov 9;9(88):35809-35812. doi: 10.18632/oncotarget.26260. eCollection 2018 Nov 9.

33.

Approach to evaluating tumor mutational burden in routine clinical practice.

Truesdell J, Miller VA, Fabrizio D.

Transl Lung Cancer Res. 2018 Dec;7(6):678-681. doi: 10.21037/tlcr.2018.10.10. Review.

34.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA.

PLoS One. 2018 Nov 27;13(11):e0208097. doi: 10.1371/journal.pone.0208097. eCollection 2018.

35.

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors.

Zhou C, Yuan Z, Ma W, Qi L, Mahavongtrakul A, Li Y, Li H, Gong J, Fan RR, Li J, Molmen M, Clark TA, Pavlick D, Frampton GM, Forcier B, Moore EH, Shelton DK, Cooke M, Ali SM, Miller VA, Gregg JP, Stephens PJ, Li T.

J Hematol Oncol. 2018 Nov 6;11(1):129. doi: 10.1186/s13045-018-0671-8.

36.

Involving Youth With a Chronic Illness in Decision-making: Highlighting the Role of Providers.

Miller VA.

Pediatrics. 2018 Nov;142(Suppl 3):S142-S148. doi: 10.1542/peds.2018-0516D.

PMID:
30385620
37.

Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.

Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM.

Oncologist. 2019 Jun;24(6):791-797. doi: 10.1634/theoncologist.2018-0334. Epub 2018 Oct 29.

PMID:
30373905
38.

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.

Schrock AB, Welsh A, Chung JH, Pavlick D, Bernicker EH, Creelan BC, Forcier B, Ross JS, Stephens PJ, Ali SM, Dagogo-Jack I, Shaw AT, Li T, Ou SI, Miller VA.

J Thorac Oncol. 2019 Feb;14(2):255-264. doi: 10.1016/j.jtho.2018.10.008. Epub 2018 Oct 24.

39.

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE Jr, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL.

Clin Cancer Res. 2019 Jan 1;25(1):277-289. doi: 10.1158/1078-0432.CCR-18-1544. Epub 2018 Oct 12.

PMID:
30314968
40.

Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.

Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio JA, Ramkissoon S, Severson E, Necchi A, Killian JK, Ali SM, Schrock AB, Liu NW, Chung J, Miller VA, Stephens PJ, Welsh A, Corona RJ, Ross JS, Bratslavsky G.

J Urol. 2019 Mar;201(3):541-548. doi: 10.1016/j.juro.2018.09.056.

PMID:
30291913
41.

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Klempner SJ, Gowen K, Lee TK, Zhu VW, Schrock AB, Miller VA, Ali SM, Ou SI.

Lung Cancer. 2018 Oct;124:86-89. doi: 10.1016/j.lungcan.2018.07.043. Epub 2018 Jul 31.

42.

Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.

Qin A, Johnson A, Ross JS, Miller VA, Ali SM, Schrock AB, Gadgeel SM.

J Thorac Oncol. 2019 Jan;14(1):54-62. doi: 10.1016/j.jtho.2018.09.014. Epub 2018 Sep 26.

PMID:
30267839
43.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ.

J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.

44.

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.

Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F.

Oncologist. 2019 Feb;24(2):219-228. doi: 10.1634/theoncologist.2018-0058. Epub 2018 Aug 14.

45.

A pilot study of observed physician-parent-child communication and child satisfaction in a gastroenterology clinic.

Becker TD, Lin HC, Miller VA.

Patient Prefer Adherence. 2018 Jul 26;12:1327-1335. doi: 10.2147/PPA.S171620. eCollection 2018.

46.

Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies.

Greenplate A, Wang K, Tripathi RM, Palma N, Ali SM, Stephens PJ, Miller VA, Shyr Y, Guo Y, Reddy NM, Kozhaya L, Unutmaz D, Chen X, Irish JM, Davé UP.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00019. Epub 2018 Feb 13.

47.

Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.

Necchi A, Bratslavsky G, Corona RJ, Chung JH, Millis SZ, Elvin JA, Vergilio JA, Suh J, Ramkissoon S, Severson E, Daniel S, Killian JK, Ali SM, Schrock AB, Reddy P, Miller VA, Welsh A, Gay LM, Ross JS.

Eur Urol Focus. 2018 Jul 16. pii: S2405-4569(18)30179-2. doi: 10.1016/j.euf.2018.07.013. [Epub ahead of print]

PMID:
30025711
48.

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.

Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN Jr, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB.

J Thorac Oncol. 2018 Oct;13(10):1560-1568. doi: 10.1016/j.jtho.2018.06.019. Epub 2018 Jul 5.

49.

Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.

Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D.

J Mol Diagn. 2018 Sep;20(5):686-702. doi: 10.1016/j.jmoldx.2018.05.004. Epub 2018 Jun 22.

50.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

Supplemental Content

Loading ...
Support Center